Ascensia Diabetes Care announced today that a new study demonstrates reduced out-of-target blood glucose ranges with its Contour system.

The company, which distributes Senseonics’ Eversense continuous glucose monitor (CGM), develops the Contour blood glucose monitoring (BGM) systems and the Contour diabetes app (CDA) for people with diabetes who are managing their blood glucose levels.

According to a news release, the new study — presented at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2022 in Barcelona — showed that people who used the connected Contour BGM systems and app for at least six months can see a reduced frequency of hypoglycemic and hyperglycemic blood glucose readings (BGRs). Ascensia said the data suggests the key benefit of using the systems to avoid out-of-target blood glucose ranges that can lead to serious health complications.

The study assessed data from 7,047 Contour system users in Australia. After six months, the estimated frequency of BGRs in high and very high ranges of people using the system fell by more than 6.5 times and 5.6 times, respectively, compared to baseline.

Ascensia said the decrease was more prominent among users who reported the use of oral antidiabetic medications. Decrease of BGRs in the low range was modest at 1.2 times in the entire study population and registered at 1.38 times in Contour users who were treated with insulin and are more prone to hypoglycemic events.

The majority of those assessed had type 2 diabetes (66.9%).

“We’re pleased to see results from the study showcasing that our CDA system is helping people with diabetes to manage their condition,” Ascensia Head of BGM Marketing and Strategy Frank Held said in the release. “While many diabetes apps support people with diabetes in managing their condition, they don’t all provide alerts or guidance for hypoglycaemic or hyperglycaemic events, like the Contour diabetes app does. Failure to properly address these events can result in serious health complications, so it is crucial that monitoring systems and connected apps facilitate the detection of high and low blood glucose levels.”